2024-11-20 - Analysis Report
## Colgate-Palmolive Co (CL) Stock Review

This report analyzes Colgate-Palmolive Co (CL), a leading consumer staples company producing and marketing oral care, personal care, and household products globally, based on the provided data.

**1. Performance vs. S&P 500 (VOO):**

Colgate-Palmolive's cumulative return of 45.65% significantly lags behind the S&P 500's return of 125.6%. The difference is -79.95%, placing it at the 7.02 percentile of its historical relative performance against the S&P 500. This indicates CL underperformed the market significantly over the analyzed period.  The provided CAGR data shows inconsistent performance, ranging from negative returns to over 50% in different periods.  The high maximum drawdown (MDD) values also highlight periods of significant risk. Beta values generally range from 0.3 to 0.7, suggesting lower than average market volatility.

**2. Recent Price Movement:**

* **Last Price:** $93.61
* **5-Day Moving Average:** $92.86
* **20-Day Moving Average:** $93.78
* **60-Day Moving Average:** $99.86

The price is slightly below the 20-day moving average, indicating a recent downward trend. The significant gap between the current price and the 60-day moving average suggests a more pronounced bearish trend over the past two months.


**3. Technical Indicators and Expected Return:**

* **RSI (46.43):** Suggests the stock is neither overbought nor oversold, sitting near the neutral zone.
* **PPO (0.4):** A positive value indicates a bullish momentum, although relatively weak.
* **Delta_Previous_Relative_Divergence (-6.26):**  Shows a recent weakening relative to the S&P 500.
* **Expected Return (0.0%):**  The expected return is zero, suggesting no significant alpha generation is anticipated compared to the S&P 500 for a long-term (2+ years) investment. This aligns with the historical underperformance relative to the market.  The current price of $93.61 doesn't show a significant deviation from the moving averages that would suggest a sudden drastic move (up or down).

**4. Recent Financials and Outlook:**

The provided quarterly earnings data shows relatively stable revenue around $5 billion, with a slight downward trend from Q1 2024. EPS remains relatively stable around $0.8-0.9.  The lack of forward-looking estimates makes a comprehensive financial outlook difficult.  Further analysis requires a more detailed breakdown of earnings calls and future projections by analysts.

**6. Financial Data Analysis:**

* **Revenue and Profitability:** Revenue remains relatively consistent, but profit margins show a slight declining trend throughout the provided quarters. This suggests increasing cost pressure or reduced efficiency.
* **Capital and Profitability:**  ROE fluctuates wildly, indicating significant variations in profitability and potentially substantial accounting adjustments or one-time events.  The negative ROE in Q3 2023 warrants further investigation.

**7. News and Recent Issues:**

*(This section requires access to real-time news sources like Shacknews and Finbold.  Please provide the latest news articles for a complete analysis.)*  Analysis of recent earnings news, market outlook, analyst opinions, and performance highlights would be crucial to assess the current sentiment and future expectations.


**8. Overall Analysis:**

Colgate-Palmolive (CL) has significantly underperformed the S&P 500 over the analyzed period.  While recent financial statements reveal stable revenue, declining profit margins and wildly fluctuating ROE raise concerns. Technical indicators are neutral, not providing a strong buy or sell signal.  The lack of a positive expected return and the historical underperformance relative to the S&P 500 cast doubts on its long-term potential for outperformance.  Further analysis of recent news and analyst reports is needed to make informed investment decisions. The erratic ROE values require further examination to understand underlying factors.


**9. Disclaimer:** This report is for informational purposes only and should not be considered investment advice.  Conduct thorough research and consult with a financial advisor before making any investment decisions.  The analysis is limited by the scope of the provided data.
